AUTHORS
Valentina Cardenas Castro, MD, Jay R Hydren, PhD2, Jorge Arturo Hurtado Martinez, MD, MHSc3, Jennifer M Ahlstrom, BA4, Gurbakhash Kaur, MD,MA5, Rahul Banerjee, MD6, Natalie H. Strand, MD7, Hira Mian, MD8, Rafael Fonseca, MD9
AFFILIATIONS
1 Mayo Clinic Arizona, Scottsdale, Arizona, United States
2 HealthTree Foundation, South Jordan, Utah, United States
3 HealthTree Foundation, South Jordan, Utah, United States
4 HealthTree Foundation, South Jordan, Utah, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United Kingdom
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Mayo Clinic Arizona, Scottsdale, Arizona, United States
8 McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario, Canada
9 Mayo Clinic Arizona, Scottsdale, Arizona, United States
ABSTRACT
Background: Bortezomib is a cornerstone component of induction therapy for multiple myeloma, but bortezomib-induced peripheral neuropathy (BIPN) remains a dose-limiting toxicity affecting patient outcomes and quality of life.
Methods: HealthTree Foundation conducted a patient-reported outcomes survey of 415 patients with multiple myeloma who had received bortezomib during any line of treatment. The survey assessed BIPN symptom frequency, severity, management strategies, impact on daily functioning, and recovery patterns after treatment discontinuation. Side effect severity was assessed on a 5 point scale: 1-hardly noticeable, 2-uncomfortable but manageable, 3-disruptive to my life, 4-severely disruptive to my life, and 5-unmanageable, stopped treatment. Open-ended responses were analyzed qualitatively.
Results: The cohort was 51.8% female with median age 70 years (IQR: 65-75; 53.5%; aged 70+) and 44.6% White. Most patients (95%) had first received bortezomib during frontline therapy, primarily starting >5 years ago (46.4%) or 2-5 years ago (28.2%). While 51.6% of patients had stopped taking bortezomib ≥2 years ago, 12.3% of patients were still taking it at survey administration. Subcutaneous administration was most common (75.8%). Only 15.5% of patients received biweekly administration. The median duration of therapy was 6 months or less.
Tingling, burning, and numbness in hands and/or feet were the predominant manifestations of BIPN, with 57.1% identifying symptoms that were uncomfortable but manageable for their worst specific symptom. BIPN was disruptive to 24% of people and severely disruptive in 5%. Balance abnormalities were reported anywhere from daily to monthly in 49% of patients (severity ≥3 in 18.7%), pain in 40.5% (severity ≥3 in 10.1%), tingling in 76% (severity ≥3 in 24%), and daily weakness in 18% (severity ≥3 in 10.8%). When asked whether they think about neuropathy daily 35% agreed and 24% strongly agreed. Furthermore, 43% noted activity interference.
Dose modification and treatment discontinuation were frequently required due to symptom severity.
Among respondents answering post-discontinuation trajectory, 36.4% reported partial or full resolution and 53.4% experienced unchanged or worsening symptoms, for 10.2% the question did not apply.
Nonlinear GLM (gamma family, log link) and Kruskal-Wallis testing confirmed no significant association between route, dosing frequency, or duration and recovery time after adjustment for multiple comparisons (all adjusted p > 0.05; unadjusted dosing p = 0.02). Patients stopping bortezomib >5 years ago reported similar symptom improvement compared to those stopping <6 months ago (39.2% vs. 38.9%). This indicates BIPN recovery is independent of modifiable administration parameters and does not predictably resolve over time.
Qualitative topic analysis of open-ended responses revealed profound impacts on sleep (chronic nighttime pain preventing rest), mobility (fear of falling, wheelchair dependence), fine motor skills (difficulty with buttoning, writing), and independence (loss of ability to drive, shop, or attend social events).
Concerningly, 36% of patients disagreed or strongly disagreed that they felt informed about neuropathy risks prior to starting treatment. The persistent burden of these symptoms led 27% of respondents to question if the treatment's benefits were worth the side effects. Furthermore, 20% indicated they would have preferred a less effective treatment if it meant avoiding neuropathy. Qualitative analysis of open-ended responses revealed that these symptoms often persisted 5 to 10 years after completing therapy, profoundly disrupting sleep, mobility, and independence long after their cancer was controlled.
Conclusions: BIPN significantly impacts patient quality of life and treatment trajectories, with recovery patterns that appear independent of how the drug was administered or duration of therapy. Qualitative analysis revealed that the burden extends beyond expected sensory symptoms to include systemic effects (bowel incontinence, erectile dysfunction, hearing loss) and profound disruption of daily function and independence. These findings emphasize the need for improved patient education about the persistent nature of BIPN regardless of dosing strategy, standardized neuropathy monitoring throughout treatment, and research into interventions that may promote nerve recovery beyond simply modifying or discontinuing bortezomib dosing.
DISCLOSURES
Valentina Cardenas Castro, MD: No relevant conflicts of interest to declare.